Related Experiment Videos
Does progesterone treatment influence risk factors for recurrent preterm delivery?
Paul J Meis1, Mark Klebanoff, Mitchell P Dombrowski
1National Institute of Child Health and Human Development, Rockville, Maryland, USA. pmeis@wfubmc.edu
Obstetrics and Gynecology
|September 2, 2005
Summary
Progesterone treatment significantly reduces the risk of recurrent preterm delivery, particularly for women with a history of multiple preterm births. It alters the impact of certain risk factors on preterm birth prevention.
Area of Science:
- Reproductive Medicine
- Maternal-Fetal Medicine
- Clinical Pharmacology
Background:
- Recurrent preterm delivery remains a significant challenge in obstetrics.
- Identifying risk factors and effective preventative strategies is crucial for improving neonatal outcomes.
- 17alpha-hydroxyprogesterone caproate is used to prevent preterm birth, but its effect on risk factor modification is less understood.
Purpose of the Study:
- To investigate how demographic and pregnancy characteristics influence recurrent preterm delivery risk.
- To determine if 17alpha-hydroxyprogesterone caproate modifies the effectiveness of these risk factors in prevention.
Main Methods:
- Secondary analysis of a randomized trial involving 17alpha-hydroxyprogesterone caproate and placebo groups.
- Examined associations between risk factors and preterm delivery (<37 weeks) in women at risk.
- Risk factors included number of previous preterm deliveries and penultimate delivery status.
Main Results:
- Previous preterm deliveries were significant risk factors in both groups.
- 17alpha-hydroxyprogesterone caproate negated the risk associated with multiple prior preterm deliveries.
- Obesity was protective in the placebo group but not with progesterone treatment.
Conclusions:
- 17alpha-hydroxyprogesterone caproate reduces overall preterm delivery risk in women with prior preterm birth.
- The treatment alters the epidemiological landscape of risk factors for recurrent preterm delivery.
- Specifically, it mitigates the heightened risk from a history of more than one preterm delivery.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:52Regression Toward the Mean
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...